All In Biotech

Drug Trial Radar · NCT03664180

Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

Randomized Comparison of Anticoagulation After Primary Percutaneous Coronary Intervention Using Enoxaparin, ACT Guided Unfractionated Heparin or Bivalirudin Prolongation vs. no Anticoagulation To Improve Clinical Outcome

Last checked: Nov 20, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,989 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,989

Actual

Start

Jan 11, 2019

Primary completion

Nov 23, 2022

Study completion Nov 23, 2022

Sponsor

Lead sponsor
Beijing Anzhen HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chinese Academy of Medical Sciences, Fuwai Hospital; Groupe Hospitalier Pitie-Salpetriere
First posted
Sep 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The RIGHT study is a large randomized study dedicated to post-PPCI anticoagulation in STEMI patients. The investigators propose to evaluate the clinical efficacy and safety of anticoagulation prolonged for at least 48 hours after the procedure vs. no prolongation of anticoagulation after procedure in patients with STEMI treated with bivalirudin during PPCI (primary hypothesis). When allocated to anticoagulation prolongation by randomization, the subject will be assigned to UFH, enoxaparin or bivalirudin (same regimen allocated by centre) for at least 48 hours after PPCI. The results from this study are expected to provide guidance on the risk/benefit of post-procedural anticoagulation in patients with STEMI.

Conditions

  • STEMI - ST Elevation Myocardial Infarction

Interventions

  • BivalirudinDrug

    IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later

  • EnoxaparinDrug

    40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later

  • Unfractionated heparinDrug

    IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later

  • Bivalirudin placeboDrug

    Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later

  • Enoxaparin placebo syringeDrug

    Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.

  • Unfractionated heparin placeboDrug

    Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary efficacy endpoint - number of event of a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel)Time frame: 30 days
  2. Primary safety endpoint - The number of event of major bleedingTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.